Get started
Author

Shivam Rai

Organizational resilience and social-economic sustainability: COVID-19 perspective
2021 · Siddharth Shankar Rai, Shivam Rai, et al. · Environment Development and Sustainability · 288
PDF
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms
2019 · Tata Nageswara Rao, Nils Hansen, et al. · Blood · 83
PDF
Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
2022 · Shivam Rai, Elodie Grockowiak, et al. · Nature Communications · 82
PDF
IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2 -mutant hematopoietic stem cells
2024 · Shivam Rai, Yang Zhang, et al. · Blood Advances · 46
PDF
Role of event personality and exhibitors’ eudaimonic and hedonic happiness in predicting event advocacy intentions
2018 · Shivam Rai, Jogendra Kumar Nayak · International Journal of Event and Festival Management · 28
Hospitality branding in emerging economies: an Indian perspective
2019 · Shivam Rai, Jogendra Kumar Nayak · Journal of Tourism Futures · 27
PDF
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN
2024 · Marc Usart, Nils Hansen, et al. · Blood Advances · 26
PDF
Individual differences and moral disengagement in Pay-What-You-Want pricing
2022 · Preeti Narwal, Shivam Rai · Journal of Business Research · 20
Assessing Customers' Moral Disengagement from Reciprocity Concerns in Participative Pricing
2021 · Preeti Narwal, J. K. Nayak, et al. · Journal of Business Ethics · 20
MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages
2020 · Ronny Nienhold, Peter Ashcroft, et al. · Blood · 19
Conceptualization and development of event experience scale: lessons from India
2019 · Shivam Rai, Jogendra Kumar Nayak · Tourism Review · 18
Lean Practices in Homestay Operations: A Case Study
2020 · Siddharth Shankar Rai, Irfan Ahmed Ansari, et al. · Journal of Quality Assurance in Hospitality & Tourism · 17
The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)
2022 · Shivam Rai, Jan Stetka, et al. · Blood · 16
IL-1β Secreted from Mutant Cells Carrying JAK2-V617Ffavors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression
2019 · Shivam Rai, Nils Hansen, et al. · Blood · 15
The Essence and Measurement of Trade Show Event Experiences
2019 · Shivam Rai, Jogendra Kumar Nayak · Event Management · 15
Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms
2023 · Damien Luque Paz, Michael S. Bader, et al. · HemaSphere · 14
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms
2023 · Jan Stetka, Marc Usart, et al. · Blood · 14
PDF
Examining the impact of external reference prices on seller price image dimensions and purchase intentions in pay what you want (PWYW)
2021 · Shivam Rai, Preeti Narwal · Asia Pacific Journal of Marketing and Logistics · 13
Tracking of epigenetic changes during hematopoietic differentiation of induced pluripotent stem cells
2019 · Olivia Cypris, Joana Frobel, et al. · Clinical Epigenetics · 11
PDF
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
2024 · Edo Kapetanovic, Cédric R. Weber, et al. · Nature Biomedical Engineering · 8
PDF
Combination of 5-Azacytidine and Pegifna Is Able to Overcome Resistance in JAK2-V617F Positive MPN with Loss of Dnmt3a
2022 · Melissa Lock, Damien Luque Paz, et al. · Blood · 5
Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F
2025 · Marc Usart, Quentin Kimmerlin, et al. · Leukemia · 3
Inhibiting Glutamine Metabolism with CB-839 Reduces Erythrocytosis in MPN Mice
2021 · MARC Usart, Shivam Rai, et al. · Blood · 2
AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)
2025 · Marc Usart, Shivam Rai, et al. · Blood · 1
PDF
Cellular Barcoding of JAK2-V617F Hematopoietic Stem Cells Reveals No Substantial Preferences in the Contribution of Individual Stem Cell Clones to Erythroid Versus Megakaryocytic Lineages
2023 · Marc Usart, Tiago Almeida, et al. · Blood · 1
Works count: 32
Citation count: 793
H-index: 15
I10-index: 19
Year
Topic
Type